CERSHIGH SIGNALFINANCIAL10-K

CERS shows concerning financial deterioration with operating cash flow declining substantially while debt doubled and current liabilities grew meaningfully.

The company faces a troubling liquidity situation as operating cash flow dropped substantially to $4.8M while current liabilities expanded to over $100M, creating potential working capital pressures. The doubling of total debt to $20M alongside rising interest expense suggests increased financial leverage at a time when cash generation is weakening.

Comparing 2026-03-02 vs 2025-02-26View on EDGAR →
FINANCIAL ANALYSIS

CERS presents a mixed but concerning financial picture with revenue growing 30.7% to $51.3M and gross profit expanding substantially, yet operating cash flow declined substantially to just $4.8M. The balance sheet shows stress signals with total debt doubling to $20M, current liabilities rising to $100.8M, and inventory growing 47% to $56.1M. While the company reduced its operating loss and net loss meaningfully, the sharp deterioration in cash generation combined with rising debt levels and current liabilities suggests mounting financial pressure despite top-line growth.

FINANCIAL STATEMENT CHANGES
Total Debt
Balance Sheet
+100%
$10.0M$20.0M

Debt increased 100% — substantial leverage increase; assess whether deployed for growth or covering losses.

Current Liabilities
Balance Sheet
+58.5%
$63.6M$100.8M

Current liabilities surged 58.5% — significant near-term obligations; verify ability to meet short-term debt.

Operating Cash Flow
Cash Flow
-57.4%
$11.4M$4.8M

Operating cash flow fell 57.4% — earnings quality concerns; investigate working capital changes and non-cash items.

Gross Profit
P&L
+57%
$10.8M$16.9M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Inventory
Balance Sheet
+47.1%
$38.1M$56.1M

Inventory surged 47.1% — growing faster than typical sales pace; potential demand softening or supply chain overcorrection.

Interest Expense
P&L
+43.8%
$5.8M$8.4M

Interest expense surged 43.8% — significant debt increase or rising rates materially impacting earnings.

Operating Income
P&L
+39%
-$14.2M-$8.7M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Capital Expenditure
Cash Flow
+31.4%
$2.8M$3.7M

Capital expenditure jumped 31.4% — major investment cycle underway; assess returns on deployment.

Revenue
P&L
+30.7%
$39.3M$51.3M

Strong top-line growth of 30.7% — accelerating demand or successful expansion into new markets.

Net Income
P&L
+25.3%
-$20.9M-$15.6M

Net income grew 25.3% — bottom-line growth signals improving overall business health.

LANGUAGE CHANGES
NEW — 2026-03-02
PRIOR — 2025-02-26
ADDED
(1) As of February 5, 2026, there were 192,171,776 shares of the registrant s common stock outstanding.
(1) Based on a closing sale price of $1.41 per share on June 30, 2025.
Department of Defense, or DoD, due to executive orders impacting government contract funding and personnel, previous and potential future U.S.
An inability to successfully transition from a direct selling model to a kit model, as well as an inability to successfully commercialize the INTERCEPT Blood System for Cryoprecipitation in the U.S.
Adverse market and economic conditions as well as tariffs and escalating international trade tensions may exacerbate certain risks affecting our business.
+7 more — sign up free →
REMOVED
(1) As of February 6, 2025, there were 185,789,815 shares of the registrant s common stock outstanding.
(1) Based on a closing sale price of $1.76 per share on June 28, 2024.
We have very limited experience selling directly to hospitals or expertise complying with regulations governing finished biologics, and our inability to successfully commercialize the INTERCEPT Blood System for cryoprecipitation in the U.S.
Adverse market and economic conditions may exacerbate certain risks affecting our business.
We may not be able to protect our intellectual property or operate our business without infringing intellectual property rights of others.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →